drugset / Trial / NCT05833984
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter, phase 1b/2 trial of IMM01 (SIRPα Fc) plus tislelizumab in patients with advanced solid tumors and lymphomas.
Timeline
- Start
- 2022-05-17
- Primary completion
- 2024-02-07
- Completion
- 2024-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM01 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | IMM01 | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
| Subject | IMM01 | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |